News | January 21, 2026
Senores Pharmaceuticals reports stellar Q3 FY26 growth; PAT surges 105%
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
In Q3 FY26, Senores posted consolidated revenue of Rs. 175 crore, up 64% year-on-year.
The company recorded revenue of Rs. 1,065 crore in the third quarter of FY26
Within India, Dabur expects its Home & Personal Care business to deliver double-digit growth,
The company’s consolidated revenue from operations rose to Rs. 361.13 crore in Q2 FY26 and Rs. 707.67 crore for the first half
Consolidated revenue from operations stood at Rs. 111.05 crore
EBITDA was Rs. 2,359.6 crore in the quarter ended September 30, 2025
Total income for the period stood at Rs. 7101.28 crore
The CRDMO segment contributed Rs. 452.7 crore, recording a robust 70.5 per cent YoY increase
The company reported a 28% year-on-year increase in Q2 revenue to Rs. 220.9 crore
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
